Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands.
Diabet Med. 2021 Sep;38(9):e14405. doi: 10.1111/dme.14405. Epub 2020 Oct 16.
Angiotensin receptor blockers (ARBs) reduce vascular complications in diabetes independently of blood pressure. Experimental studies suggested that ARBs may restore the detoxifying enzyme glyoxalase 1, thereby lowering dicarbonyls such as methylglyoxal. Human data on the effects of ARBs on plasma dicarbonyl levels are lacking. We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux.
We analysed a subset of the Irbesartan in Patients with T2D and Microalbuminuria (IRMA2) study. We measured plasma dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs and d-lactate using ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) in the treatment arm receiving 300 mg irbesartan (n = 121) and a placebo group (n = 101) at baseline and after 1 and 2 years. Effect of treatment was analysed with repeated measurements ANOVA.
There was a slight, but significant difference in baseline median methylglyoxal levels [placebo 1119 (907-1509) nmol/l vs. irbesartan 300 mg 1053 (820-1427) nmol/l], but no significant changes were observed in any of the plasma dicarbonyls over time in either group and there was no effect of irbesartan treatment on plasma free AGEs or d-lactate levels at either 1 or 2 years.
Irbesartan treatment does not change plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs or d-lactate in type 2 diabetes. This indicates that increased dicarbonyls in type 2 diabetes are not targetable by ARBs, and other approaches to lower systemic dicarbonyls are needed in type 2 diabetes. (Clinical Trial Registry No: #NCT00317915).
血管紧张素受体阻滞剂(ARB)可独立于血压降低糖尿病的血管并发症。实验研究表明,ARB 可能恢复解毒酶糖氧还蛋白 1,从而降低二羰基化合物,如甲基乙二醛。关于 ARB 对血浆二羰基水平影响的人类数据尚缺乏。我们在 2 型糖尿病患者中研究了厄贝沙坦是否降低了血浆中二羰基甲基乙二醛、乙二醛、3-脱氧葡萄糖酮及其衍生的晚期糖基化终产物(AGEs)水平,并增加了 d-乳酸,反映了更大的甲基乙二醛通量。
我们分析了 Irbesartan 在 2 型糖尿病和微量白蛋白尿患者中的研究(IRMA2)的一个亚组。我们使用超高效液相色谱串联质谱法(UPLC-MS/MS)在基线和治疗组(n=121)和安慰剂组(n=101)接受 300mg 厄贝沙坦和接受安慰剂时测量血浆中二羰基甲基乙二醛、乙二醛和 3-脱氧葡萄糖酮、游离 AGEs 和 d-乳酸。使用重复测量方差分析分析治疗效果。
基线中位数甲基乙二醛水平略有差异[安慰剂 1119(907-1509)nmol/L 与厄贝沙坦 300mg 1053(820-1427)nmol/L],但两组在任何时间点的血浆中二羰基化合物均未发生显著变化,厄贝沙坦治疗对血浆游离 AGEs 或 d-乳酸水平在 1 年或 2 年均无影响。
厄贝沙坦治疗不能改变 2 型糖尿病患者血浆中二羰基甲基乙二醛、乙二醛和 3-脱氧葡萄糖酮、游离 AGEs 或 d-乳酸水平。这表明 2 型糖尿病中二羰基化合物的增加不能通过 ARB 靶向,需要在 2 型糖尿病中采用其他方法降低全身二羰基化合物。(临床试验注册号:#NCT00317915)。